| Florencia Santos Cruz, MD | |
|
5645 Main St, Flushing, NY 11355-5045 | |
| (718) 670-1033 | |
| (516) 437-4167 |
| Full Name | Florencia Santos Cruz |
|---|---|
| Gender | Female |
| Speciality | Pediatrics - Neonatal-perinatal Medicine |
| Location | 5645 Main St, Flushing, New York |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083650808 | NPI | - | NPPES |
| 0004596 | Medicaid | NJ | |
| 02704227 | Medicaid | NY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2080N0001X | Pediatrics - Neonatal-perinatal Medicine | 25MA0699900 (New Jersey) | Secondary |
| 2080N0001X | Pediatrics - Neonatal-perinatal Medicine | 238117 (New York) | Primary |
| Entity Name | Tjh Medical Services Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184670465 PECOS PAC ID: 8527960533 Enrollment ID: O20040121000802 |
News Archive
Alimera Sciences, Inc., a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the United Kingdom's National Institute for Health and Clinical Excellence (NICE) has issued final draft guidance indicating that ILUVIEN is not recommended for the treatment of chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.
Severe forms of coronavirus disease (COVID-19) linked to high mortality rates might arise in a minority of fully-vaccinated individuals with many co-occurring medical conditions, finds a recent study by Israeli researchers published in the journal Clinical Microbiology and Infection.
IVAX Diagnostics, Inc. announced today that its U.S. subsidiary headquartered in Florida, Diamedix Corporation, has filed a 510(k) premarket submission with the U.S. Food and Drug Administration ("FDA") for its next -generation fully automated Enzyme-linked Immunosorbent Assay ("ELISA") system for autoimmune and infectious disease testing, named the Mago®4S.
InterMune, Inc. today announced additions to its senior leadership team to prepare for the commercialization of Esbriet™ (pirfenidone) in Europe. InterMune's Marketing Authorization Application (MAA) for Esbriet received a positive CHMP opinion that is now awaiting ratification by the European Commission.
Both boys and girls who are victims of bullying, including bullying through e-mail and the internet, are at elevated risk for depression. However, according to a new study, adolescent girls may engage in substance use as a result of bullying-related depression.
› Verified 5 days ago
| Entity Name | Jamaica Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477505220 PECOS PAC ID: 2264324334 Enrollment ID: O20040427001519 |
News Archive
Alimera Sciences, Inc., a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the United Kingdom's National Institute for Health and Clinical Excellence (NICE) has issued final draft guidance indicating that ILUVIEN is not recommended for the treatment of chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.
Severe forms of coronavirus disease (COVID-19) linked to high mortality rates might arise in a minority of fully-vaccinated individuals with many co-occurring medical conditions, finds a recent study by Israeli researchers published in the journal Clinical Microbiology and Infection.
IVAX Diagnostics, Inc. announced today that its U.S. subsidiary headquartered in Florida, Diamedix Corporation, has filed a 510(k) premarket submission with the U.S. Food and Drug Administration ("FDA") for its next -generation fully automated Enzyme-linked Immunosorbent Assay ("ELISA") system for autoimmune and infectious disease testing, named the Mago®4S.
InterMune, Inc. today announced additions to its senior leadership team to prepare for the commercialization of Esbriet™ (pirfenidone) in Europe. InterMune's Marketing Authorization Application (MAA) for Esbriet received a positive CHMP opinion that is now awaiting ratification by the European Commission.
Both boys and girls who are victims of bullying, including bullying through e-mail and the internet, are at elevated risk for depression. However, according to a new study, adolescent girls may engage in substance use as a result of bullying-related depression.
› Verified 5 days ago
| Entity Name | New York Queens Medicine And Surgery, P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003114851 PECOS PAC ID: 4082883673 Enrollment ID: O20110817000163 |
News Archive
Alimera Sciences, Inc., a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the United Kingdom's National Institute for Health and Clinical Excellence (NICE) has issued final draft guidance indicating that ILUVIEN is not recommended for the treatment of chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.
Severe forms of coronavirus disease (COVID-19) linked to high mortality rates might arise in a minority of fully-vaccinated individuals with many co-occurring medical conditions, finds a recent study by Israeli researchers published in the journal Clinical Microbiology and Infection.
IVAX Diagnostics, Inc. announced today that its U.S. subsidiary headquartered in Florida, Diamedix Corporation, has filed a 510(k) premarket submission with the U.S. Food and Drug Administration ("FDA") for its next -generation fully automated Enzyme-linked Immunosorbent Assay ("ELISA") system for autoimmune and infectious disease testing, named the Mago®4S.
InterMune, Inc. today announced additions to its senior leadership team to prepare for the commercialization of Esbriet™ (pirfenidone) in Europe. InterMune's Marketing Authorization Application (MAA) for Esbriet received a positive CHMP opinion that is now awaiting ratification by the European Commission.
Both boys and girls who are victims of bullying, including bullying through e-mail and the internet, are at elevated risk for depression. However, according to a new study, adolescent girls may engage in substance use as a result of bullying-related depression.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Florencia Santos Cruz, MD Po Box 27842, New York, NY 10087-7842 Ph: (718) 670-1651 | Florencia Santos Cruz, MD 5645 Main St, Flushing, NY 11355-5045 Ph: (718) 670-1033 |
News Archive
Alimera Sciences, Inc., a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the United Kingdom's National Institute for Health and Clinical Excellence (NICE) has issued final draft guidance indicating that ILUVIEN is not recommended for the treatment of chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.
Severe forms of coronavirus disease (COVID-19) linked to high mortality rates might arise in a minority of fully-vaccinated individuals with many co-occurring medical conditions, finds a recent study by Israeli researchers published in the journal Clinical Microbiology and Infection.
IVAX Diagnostics, Inc. announced today that its U.S. subsidiary headquartered in Florida, Diamedix Corporation, has filed a 510(k) premarket submission with the U.S. Food and Drug Administration ("FDA") for its next -generation fully automated Enzyme-linked Immunosorbent Assay ("ELISA") system for autoimmune and infectious disease testing, named the Mago®4S.
InterMune, Inc. today announced additions to its senior leadership team to prepare for the commercialization of Esbriet™ (pirfenidone) in Europe. InterMune's Marketing Authorization Application (MAA) for Esbriet received a positive CHMP opinion that is now awaiting ratification by the European Commission.
Both boys and girls who are victims of bullying, including bullying through e-mail and the internet, are at elevated risk for depression. However, according to a new study, adolescent girls may engage in substance use as a result of bullying-related depression.
› Verified 5 days ago
Alicia Marie Mcbride, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 5645 Main St Fl 1, Flushing, NY 11355 Phone: 718-670-1800 | |
David Ko, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 13743 45th Ave, Flushing, NY 11355 Phone: 929-362-3006 Fax: 929-362-3026 | |
Efthemia Nicolopoulos, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 5645 Main St, Flushing, NY 11355 Phone: 718-670-1800 Fax: 516-437-4167 | |
Lori R Hoch, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 14149 70th Rd, Flushing, NY 11367 Phone: 718-268-5282 | |
Kathleen Phung, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 13743 45th Ave, Flushing, NY 11355 Phone: 929-362-3006 Fax: 929-362-3026 | |
Dr. Alan Davis, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 5645 Main St, Flushing, NY 11355 Phone: 718-670-1033 | |
Pinchi Sundaram Srinivasan, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 5645 Main St, Flushing, NY 11355 Phone: 718-670-1800 |